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Cyclin-dependent kinase 9 (CDK9), a key regulator of RNA-polymerase II, is a candidate drug target for cancers
driven by transcriptional deregulation. Here we report a multi-omics-profiling of prostate cancer cell responses to
CDK9 inhibition to identify synthetic lethal interactions. These interactions were validated using live-cell imaging,
mitochondrial flux-, viability- and cell death activation assays. We show that CDK9 inhibition induces acute
metabolic stress in prostate cancer cells. This is manifested by a drastic down-regulation of mitochondrial
oxidative phosphorylation, ATP depletion and induction of a rapid and sustained phosphorylation of AMP-activated
protein kinase (AMPK), the key sensor of cellular energy homeostasis. We used metabolomics to demonstrate that
inhibition of CDK9 leads to accumulation of acyl-carnitines, metabolic intermediates in fatty acid oxidation (FAO).
Acyl-carnitines are produced by carnitine palmitoyltransferase enzymes 1 and 2 (CPT), and we used both genetic
and pharmacological tools to show that inhibition of CPT-activity is synthetically lethal with CDK9 inhibition. To our
knowledge this is the first report to show that CDK9 inhibition dramatically alters cancer cell metabolism.
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Uncontrolled growth of cancer cells requires significant metabolic
reprogramming to satisfy the requirements of rapidly dividing cells. Most
cancers have increased appetite for glucose, which allows evaluation of the
tumor-burden using glucose-positron emission tomography (PET) [1].
Prostate cancer, the most common cancer in males in the USA [2], is not
always readily detectable using PET-imaging, but can instead be
visualized using 11C-acetate due to higher dependency of prostate cancer
cells on lipids for energy production [3,4].
Normal prostate tissue and prostate cancer have specific metabolic
features that are distinct from the rest of the body. In the
untransformed state, cells of the prostate gland accumulate high
levels of citrate due to prostate-specific accumulation of zinc [5,6].
High zinc concentration inhibits m-aconitase activity and citrate
oxidation, truncating the TCA cycle and reducing ATP production
[7]. Some of the prostate-specific metabolic features may be utilized
to sensitize prostate cancer cells to other treatments.Cell division requires a substantial amount of ATP and continuous
synthesis of macromolecules, especially nucleic acids and lipids.
Direct crosstalk between metabolism and the cell-cycle regulators,
cyclin-dependent kinases (CDKs), could integrate nutrient
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crosstalk in the literature. For example, increased glucose uptake can
activate oncogenic signaling in nonmalignant cells [8]. Conversely,
CDK1, the major regulator of the G2/M cell cycle transition is also
targeted to mitochondria, where it phosphorylates proteins of the
complex 1 electron-transport machinery to promote ATP production
[9]. In addition, CDK4 and CDK6, regulators of the G1-S transition,
can also directly regulate glucose metabolism [10,11]. Increased
activity of CDKs is observed in most cancers, which has fostered
development of CDK inhibitors for cancer therapy.
Regulation of cell cycle initiation and progression is ultimately
dictated through transcriptional regulation. A specific class of CDKs
phosphorylate the RNA-polymerase II (RNA-Pol II) carboxy-
terminal domain (CTD) to regulate its activity [12,13]. CDK7 and
CDK9 are the major RNA-Pol II CDKs. CDK7 promotes
transcription initiation, while the switch to productive elongation is
dependent on CDK9. CDK7 additionally functions as a CDK-
activating kinase and inhibition of its activity will directly affect both
cell cycle CDKs and RNA-Pol II [14]. On the other hand, CDK9 has
a well-defined primary function, and several reports suggest that this
enzyme could be an attractive target for prostate cancer therapy.
First, CDK9-mediated phosphorylation regulates the activity of
the androgen receptor, the major drug-target in prostate cancer
[15]. Second, CDK9 is required for RNA-Pol II pause-release, a
process that is frequently deregulated in cancer cells [16,17].
Third, compounds targeting CDK9 induce apoptosis in cancer
cells, in part through decreased expression of the anti-apoptotic
proteins [18]. These data position CDK9 as an attractive target
for cancer therapy.
In this study, we show that the pan-CDK inhibitor AT7519
induces acute metabolic stress in prostate cancer cells. Metabolite
profiling showed that AT7519 treatment led to accumulation of acyl-
carnitines. We identify CDK9 as the key mediator of the observed
metabolic effects in prostate cancer cells and show that
simultaneous inhibition of CDK9 and enzymes required for
acyl-carnitine production (CPT1 and CPT2) is lethal to prostate
cancer cells. In brief, our study reports a CDK9 inhibition-
induced adaptive metabolic response in prostate cancer cells, and
thereby identifies a candidate compound combination for prostate
cancer therapy.
Materials and Methods
Cell Culture and ManipulationsLNCaP and PC3 cells were obtained from ATCC and maintained
as recommended by the provider. AT7519 (used in a dose of 0.5 μM
unless otherwise indicated) and Etomoxir were purchased from
Selleckchem. Perhexiline (used in a dose of 10 μM unless otherwise
indicated) was purchased from Sigma. NVP2 was from MedChem
Express. Viability assays were performed using the CellTiter-Glo
Luminescent Cell Viability Assay (Promega). Growth rate and cell
death activation were evaluated using the Incucyte instrument
according to manufacturer's instructions. For detection of cell death
activation, we used IncuCyte Caspase-3/7 Green Reagent for
Apoptosis (Essen Biosciences). Cell cycle analysis was performed
using the Propidium Iodide Flow Cytometry Kit (Abcam, ab139418)
and the BD FACSCanto instrument (BD Biosciences). Knockdown
experiments were performed using RNAiMax reagent (Sigma). CPT1targeting siRNAs were from ThermoFisher Scientific (siCPT1a s3467
and siCPT2 s3468).
Seahorse Metabolic Flux Analysis
Metabolic flux analysis was performed using a Seahorse XFe 96
instrument. An equal number of LNCaP cells were plated and
allowed to attach for 1 day. Cells were treated with inhibitors for 24
hours and subjected to flux analysis. In brief, cells were changed to
base media containing 1 mM pyruvate, 2 mM glutamine and 10 mM
glucose 45 minutes before the assay. Cartridge was equilibrated
overnight and loaded with Oligomycin 2 μM, FCCP 1 μM and
rotenone/antimycin A 0.5 μM prior to the assay. Results were
analyzed using Seahorse Wave software.
Protein Profiling
Samples for western blotting were prepared as previously described
[19]. Samples for the reverse-phase protein array profiling were
prepared using the same protocol. Antibodies used are as follows:
from Cell Signaling Technology, Cl-PARP (9541), p-H2AX (9718),
p-h3ser10 (9701), CPT1A (12252), h3 (9715), HES1 (11988),
CDK1 (9116), p-RNA Pol II-Ser 2 (13499), MCL1 (5453 T) and
MYC (5605S). Actin (ab49900), CPT2 (ab181114) and GAPDH
(9485) antibodies were from Abcam.
mRNA Profiling
RNA isolation was performed using the illustraMiniSpin-kit
(GE Healthcare) according to manufacturer's instructions, except
luciferase RNA (Promega, cat # L4561) was added into cell lysis
buffer. cDNA was synthesized using the qScript cDNA Synthesis Kit
(Quantabio). Primers used are as follows: MYC F- TACCC
TCTCAACGACAGCAG, R- TCTTGACATTCTCCTCGGTG;
MCL1 F- TGCTTCGGAAACTGGACATCA, R-TAGCCACA
AAGGCACCAAAAG and Luciferase F-TACAACACCCC
AACATCTTCGA, R- GGAAGTTCACCGGCGTCAT.
Metabolomic Profiling
LNCaP cells were allowed to attach for 1 day and treated for 1 day.
For harvesting, cells were washed with PBS, trypsinized, counted and
centrifuged 4000 rpm for 5 minutes at 4 °C, washed with PBS,
centrifuged again, pellet was washed with water (cells not solubilized),
cells were frozen using liquid nitrogen and stored at −80 °C until
analysis. Targeted metabolomics was purchased as a service from
FIMM Metabolomics/Lipidomics/Fluxomics Unit (Helsinki
Finland).
Results
CDK Inhibitor AT7519 Induces Acute Metabolic Stress in
Prostate Cancer Cells
Cyclin-dependent kinase (CDK) inhibitors suppress cell cycle
progression, but there has been no study on how the prostate cancer
cell proteome is altered in response to CDK inhibition. In order to
characterize these changes, we used AT7519, a pan-CDK-inhibitor
that most potently targets CDK9 [20].
We wanted to identify both immediate and sustained changes in
the proteome using reverse-phase protein arrays (RPPA), and
therefore analyzed two time-points, 4 and 24 hours after treatment
with AT7519. In order to identify adaptive changes that enable cell
survival, we selected a dose (500 nM) that decreased the proliferation
rate of cells but did not induce substantial cell death as measured by
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Figure 1, A and B). We hypothesized that proteins whose expression
changes rapidly and in a sustained manner report on the most
essential adaptations for cancer cell survival. We identified two targets
whose levels were significantly increased at both time points, the
phosphorylated form of AMP-activated protein kinase (AMPK) and
the serine/threonine-protein kinase A-Raf (Figure 1A and Suppl.
Table 1). Lopez-Mejia et al. (2017) have reported that CDK4-
mediated phosphorylation of AMPK increases glycolysis and
decreases fatty acid oxidation in mouse embryonic fibroblasts [21].
However, the RPPA-data showed that inhibition of CDK-activity
using AT7519 induced phosphorylation of AMPK in prostate cancer
cells. AMPK is one of the key regulators of cellular energy homeostasis
and is canonically activated in response to an increased AMP/ATP
ratio [22]. As detailed in the introduction, prostate cancer cells have
unique metabolic features, and we speculated that phosphorylation of
AMPK in response to AT7519 might represent a prostate cancer-
specific metabolic response. We therefore focused on AMPK, and
first confirmed by western blotting that AMPK phosphorylation is
indeed induced in a dose-dependent manner in response to AT7519
treatment (Figure 1B). Activation of AMPK in response to AT7519
suggested that the treatment might decrease cells' ability to produce
ATP.
We directly measured the cellular oxygen-consumption rate (OCR)
to assess if AT7519 affects the rate of ATP production. AT7519 dose-A B
D
Figure 1. AT7519 treatment induces acute metabolic stress. A) AMP
recorded using the reverse-phase protein array (RPPA)-approach (all th
0.5 μM AT7519 for 4 and 24 hours and cell lysates were analyzed u
replicates with SEM and Student's t-test was used to evaluate statist
DMSO or increasing dose of AT7519 for 24 hours and samples were a
the abundance of each protein. This is a representative western blot o
oxygen-consumption rate (OCR) in LNCaP cells. Cells were treated wit
XFe 96 analyzer OCR-measurements. Serial injections of oligomycin (O
and a mix of rotenone and antimycin (Rot+AA) enabled measuremen
respiration, respectively. Proton leak and spare respiratory capacity w
shown is an average of 3–4 biological replicates with SEM and Stud
**b.01, ***b.001).dependently inhibited mitochondrial oxygen consumption and ATP
production (Figure 1, C and D). Basal respiration-, maximal
respiration- and proton leak-dependent OCR were also decreased,
but coupling efficiency was maintained. These data indicate that the
activity of the mitochondria decreases in response to AT7519
treatment, but the mitochondria remain functional.
We have so far shown that a low dose of AT7519 induces acute
metabolic stress in prostate cancer cells. The dose selected led to a strong
decrease in cells' ability to produce ATP but did not induce apparent cell
death. We therefore hypothesized that cells activate alternative
metabolic strategies to enable survival in the presence of AT7519.
AT7519 Induces Accumulation of Acyl-Carnitines
We performed metabolite profiling to probe the possibility
that AT7519 affects metabolites involved in ATP generation.
Targeted mass spectrometry was used to quantify ~100 different
metabolites, including amino acids, nucleotides, neurotransmitter
intermediates, choline metabolites and enzyme cofactors (Figure 2A).
We noted a prominent decrease in nucleotide metabolites, including
uracil (−51%), hypoxanthine (−40%), inosine (−29%) and guanosine
(−20%). In addition, AT7519 induced a striking increase in the
abundance of the nine different acyl-carnitines measured (Figure 2, A
and B). Carnitine serves as an acyl-group carrier across the
mitochondrial membrane in a process that delivers lipids to
mitochondria for fatty acid oxidation [23]. The metabolite profilingC
K phosphorylation in response to AT7519 in LNCaP cells. Data was
e data is provided in Suppl. Table 1). LNCaP cells were treated with
sing RPPA profiling. Data shown is an average of four biological
ical significance (*b.05, **b.01). B) LNCaP cells were treated with
nalyzed using western blotting. Densitometry was used to evaluate
f two replicates. C, D) AT7519 treatment decreases mitochondrial
h either DMSO or AT7519 for 24 hours prior to start of the Seahorse
lig), Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP),
ts of ATP production, maximal respiration, and non-mitochondrial
ere calculated using these parameters and basal respiration. Data
ent's t-test was used to assess the statistical significance (*b.05,
CA B
D E
Figure 2. AT7519 induced accumulation of acyl-carnitines promotes prostate cancer cell survival. A) Targeted metabolite profiling of
LNCaP cells treated as indicated for 24 hours. Data shown is an average of four biological replicates with SEM. Only metabolites whose
abundance changed at least 20% in comparison to DMSO are shown. Metabolite levels were quantitatively measured using mass
spectrometry and normalized to cell count. Control sample was set to 100% and treatments were also normalized to this. Student's t-test
was used to assess the statistical significance (*b.05, **b.01). B)Measurement of the absolute amount of carnitines. Data shown is an
average of 4 biological replicates with SEM and t-test was used to evaluate the statistical significance (*b.05). C) Schematic presentation
of acyl-carnitine transport across the mitochondrial membrane. D) Knockdown (KD) of CPT1 and CPT2 sensitizes cells to AT7519
treatment. KD was performed for 4 days as indicated, after which cells were treated with AT7519 for 3 days and viability was assessed
using the CellTiter-Glo assay. Data shown is an average of at least 3 biological replicates with SEM and t-test was used to evaluate the
statistical significance (*b.05, **b.01). E) The efficacy of CPT1 and CPT2 KD was evaluated using western blotting.
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oxidation.
We tested if the accumulation of acyl-carnitines in response to
AT7519-treatment is important for cancer cell survival. Addition and
removal of the lipid chain to and from carnitine is catalyzed by
carnitine palmitoyltransferases (CPT) 1 and 2, which are localized in
the outer and inner mitochondrial membranes, respectively [23]
(Figure 2C). These enzymes are required for acyl-carnitine
production and fatty acid oxidation, and we tested if they are part
of the adaptive response to AT7519. Knockdown of either CPT1 or
CPT2 sensitized cells to AT7519 (Figure 2, D and E).
In summary, AT7519-treatment leads to depletion of nucleotide
intermediates and accumulation of acyl-carnitines, and knockdown of
the CPT enzymes sensitizes cells to AT7519. Therefore, acyl-
carnitine accumulation appears to be an adaptive response to AT7519
treatment that promotes survival of cancer cells and represents a
metabolic switch that can be targeted. We next set out to test if
synthetic lethality between CDK inhibition and CPT inhibition
could be achieved through pharmacological approaches, which would
be applicable in a clinical setting.AT7519 and Inhibitors of Fatty Acid Oxidation are
Synthetically Lethal to Prostate Cancer Cells
In order to probe if AT7519 renders prostate cancer cells
dependent on lipids for ATP synthesis, we pre-treated cells with
AT7519 and measured mitochondrial oxygen consumption in
response to acute treatment with Perhexiline, a clinically approved
CPT inhibitor [24]. Indeed, acute treatment with Perhexiline
decreased the mitochondrial oxygen consumption of cells pretreated
with AT7519 (Figure 3A). This result is consistent with our model
that AT7519 renders prostate cancer cells more dependent on lipids
for ATP synthesis and this dependency can be targeted using
Perhexiline.
We next assessed the effects of combination treatment with
AT7519 and CPT inhibitors on viability of prostate cancer cells.
Perhexiline and Etomoxir, another FAO-inhibitor [25], dose-
dependently decreased prostate cancer cell viability as assessed by
ATP generation, and co-treatment with AT7519 additively enhanced
their effects (Supplementary Figure 2, A and B). Etomoxir is an
irreversible inhibitor of CPT1 and the compound has been used to
inhibit fatty acid oxidation in both normal and cancer cells, however,
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context, it is important to keep in mind that we have demonstrated
the anti-proliferative effect of combining AT7519 and fatty acid
oxidation inhibition not only by using Etomoxir, but also by using
Perhexiline (Supplementary Figure 2, A and B) and by knocking
down CPT1 and CPT2 (Figure 2D). Combining Perhexiline with
AT7519 led to a complete loss of cell viability in LNCaP and PC3
cells (Supplementary Figure 2B), and this compound was selected for
the future experiments.
We have shown that the metabolic adaptations induced by
AT7519 and Perhexiline converge to decrease cell viability and
searched the literature for clues to other mechanisms of decreased cell
survival besides ATP depletion, which is clearly a factor. Inhibition of
fatty acid oxidation has been shown to increase the levels of reactive
oxygen species (ROS) [31], and earlier we noted that AT7519-
treatment causes depletion of nucleotide precursors (Figure 2A). ROS
accumulation and unbalanced nucleotide levels are known to cause
DNA damage [32]. We therefore evaluated if the AT7519-
Perhexiline combination induces DNA damage using western blot.
Combining AT7519 with Perhexiline caused a greater than 9-fold
enhanced induction of the canonical DNA-damage marker p-H2AX
(Figure 3B). To further probe the mechanistic basis of the AT7519-
Perhexiline combination on viability, we evaluated cell cycle
distribution using propidium iodide-staining and flow cytometry.
Treatment with the compound combination led to a greater than 5-
fold increase in the sub-G1 population of cells (Figure 3C). A similar
effect on the cell cycle was observed in PC3 cells, another prostate
cancer cell line (Supplementary Figure 2C). Therefore, the
perhexiline-AT7519 combination induced decrease in cell viability
is explained by depletion of ATP, excessive DNA damage and
possibly by the activation the cell death response.
We assessed if the AT5719-Perhexiline combination induces
apoptosis by several assays. First, we performed western blotting and
observed a greater than 5-fold increase in PARP cleavage with a
concomitant decrease in the marker of mitotic cells, phosphorylated
h3-ser10 (Figure 3B). Second, we used live-cell imaging to measure
activation of caspases 3 and 7, the prototypical markers of apoptosis.
Combination treatment led to a 6-times higher activation of caspases
in LNCaP cells (Figure 3D). Third, we evaluated the proliferation rate
of cells treated with AT7519, Perhexiline and the combination. In
agreement with the prominent cell death activation, the combination
treatment additively decreased proliferation of LNCaP cells (Figure
3E). In addition, the AT7519-Perhexiline combination induced cell
death and resulted in growth arrest also in PC3 cells (Supplementary
Figure 3, A and B). These data establish AT7519 and Perhexiline as a
synthetically lethal compound combination to prostate cancer cells.
Simultaneous Targeting of CDK9 and Fatty Acid Oxidation is
Synthetically Lethal to Prostate Cancer Cells
As with any studies involving chemical probes, it is important to
test additional compounds that inhibit the same proposed targets, if
possible. We found that Perhexiline and Etomoxir, as well as CPT
knockdown, had similar effects on cells when combined with
AT7519 (Figure 2D and Supplementary Figure 2, A and B).
AT7519 is a pan-CDK inhibitor that most potently targets CDK9
[20], and we therefore hypothesized that CDK9 is the primary target
for the combinatorial lethality between AT7519 and Perhexiline. In
2018, a novel CDK9 inhibitor, NVP2, was identified and reported to
have 700-fold selectivity over other kinases [33]. We found thattreatment with NVP-2 led to a rapid (24 hours treatment), dose-
dependent depletion of the cellular ATP-levels at low nanomolar
concentrations (Figure 3F). In addition, and similar to AT7519,
NVP2-treatment caused activation of AMPK and resulted in down-
regulation of CDK1 and up-regulation of HES1 (Figure 3G). We
noted that 10 nM NVP2 had only a modest effect on the
phosphorylation of serine-2 of RNA Pol II CTD with clear effect
on the ATP levels (Figure 3, F and G). It is possible that the ATP
generation is very sensitive to CDK9 inhibition and in order to
further probe if NVP2 decreases transcription also in low doses, we
treated cells with NVP2 for 4 hours, isolated total RNA using cell lysis
buffer that contains spike-in luciferase RNA for normalization and
evaluated the transcript levels of MYC and MCL1, both of which
have been reported to be affected by CDK9 inhibition [33,34].
Importantly, NVP2 decreased MYC and MCL1 mRNA levels by
over 50% (Figure 3H). Based on these data, inhibition of CDK9
activity leads to a rapid decrease in transcription, which decreases
mRNAs that have short half-lives and are associated with fast
proliferation of cancer cells. In a longer time-frame, CDK9 inhibition
leads to a decrease in the metabolic activity of cells, manifested by
decreased OCR and ATP generation (Figure 1D). These data indicate
that the highly specific CDK9 inhibitor NVP2 causes similar effects
as the pan-CDK inhibitor AT7519, confirming CDK9 as a major
target for AT7519 in prostate cancer cells.
Next, we assessed if inhibition of CDK9 is sufficient to induce
synthetic lethality in combination with Perhexiline. Perhexiline
additively enhanced the effect of NVP2 on LNCaP cell viability
(Supplementary Figure 4A) and combination of 5 nM NVP2 with
Perhexiline led to a complete growth arrest (Figure 3I). A low dose of
NVP2 did not induce cell death on its own, but potentiated the effect
of Perhexiline by over 60-fold, as measured using caspase-activation,
which indicates that certain anti-proliferative effects of CDK9
inhibition are greatly enhanced by Perhexiline (Figure 3J). CDK9
inhibition has been reported to sensitize cancer cells to apoptosis
through decreased expression of MCL1 and MYC [33,35,36].
Combining NVP2 with Perhexiline led to over 50% decrease in MYC
levels but MCL1 was only modestly affected (Supplementary Figure
4B). In addition, and similar to the Perhexiline+AT7519 combina-
tion, we observed that Perhexiline enhances NVP2-induced DNA
damage (Figure 3B and Supplementary Figure 4B). These data imply
that the combination of CDK9 and FAO inhibitors does not induce
apoptosis through down-regulation of anti-apoptotic proteins but
rather through induction of excessive DNA damage; however, to fully
define the signaling pathways involved will require a comprehensive
future study.
Next, we moved on to evaluate the effect of combining CDK9 and
FAO inhibitors in PC3 cells. The combination of NVP2 with
Perhexiline decreased cell viability, induced cell death and caused
growth arrest also in PC3 cells (Supplementary Figure 5). We wanted
to further assess the ability of Perhexiline to sensitize prostate cancer
cells to a clinically relevant CDK9 inhibitor. For these experiments,
we selected TG02/SB1317, a compound that is currently in clinical
trials [34,37]. First, we identified a dose for TG02 that had only a
modest effect on cell viability as a single agent (Supplementary Figure
6A). Combining this low dose of TG02 with Perhexiline led to a
complete loss of proliferation of both LNCaP and PC3 cells
(Supplementary Figure 6B). To conclude, Perhexiline can enhance
the effects of CDK9 inhibition on prostate cancer cell proliferation.
These data confirm the model that CDK9 inhibition causes
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CPT activity, which can be targeted to achieve synthetic lethality.
Discussion
CDKs are the key regulators of cell cycle and RNA-Pol II activity, and
in this study we discovered that inhibition of CDK9 induces acute
metabolic stress in prostate cancer cells. This is, to our knowledge, the
first study to report that RNA-Pol II CTD kinase inhibition affects
metabolism. Our work highlights the complex interplay between
metabolism, transcription and the proteome, and shows the value of
multiplatform profiling of cancer cell response to cytostatic
compounds. Overall, we found that CDK9 inhibition triggers aD
A B
I
F Gmetabolic switch in prostate cancer cells so they rely more on CPT
enzymes for growth.
Development of normal prostate tissue requires significant
remodeling of mitochondrial metabolism. As a result, cells of the
prostate gland do not complete the TCA cycle and secrete high levels
of citrate [5,6]. This prostate-specific metabolic feature is important
to promote sperm survival. However, the lack of selection pressure to
maintain functionally proficient mitochondria may lead to accumu-
lation of mitochondrial mutations and defective mitochondria.
Indeed, mitochondrial genomes of normal prostate cells contain
numerous mutations that are not found in other tissues of the same
person [38]. Certain cancer-associated mitochondrial mutations areC
E
J
H
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mutations have also been reported to confer a growth advantage to
otherwise isogenic prostate cancer cells [40]. Some mitochondrial
mutations found in prostate cancer may also render cells more
sensitive to inhibitors that affect mitochondrial function.
In this study we unexpectedly found that CDK9 activity plays a
crucial role in mitochondrial function in prostate cancer cells. One
report has previously linked CDK9 activity to mitochondrial
dysfunction. In that case, chronic activation of CDK9 due to over-
expression of the cyclin-T1 partner was shown to result in
mitochondrial dysfunction in cardiac tissue [41]. Here we have
found that inhibiting CDK9 activity decreased oxidative phosphor-
ylation, rendering cells more dependent on lipids for ATP production
(Figs. 1D and 3A). Therefore, inhibiting CPT activity in combination
with CDK9 inhibition results in lethality in cell culture (Figure 3, D
and J). Notably, the observed increase in acyl-carnitines in response
to AT7519 may reflect an increased dependence on FAO or decreased
ability to deacylate (Figure 2B). The latter seems more likely as we
also observed a concomitant decrease in OCR (Figure 1D).
Nevertheless, it may be possible to combine CDK9 and CPT
inhibitors for therapeutic purposes but testing this will require
challenging animal studies.
The basal transcription machinery is operational in every cell,
however, inhibition of the kinases that phosphorylate RNA Pol II
carboxy-terminal domain (CTD) is more toxic to cancer cells than
normal cells and compounds targeting the CTD kinases are in clinical
trials [34,36,42,43]. The activity of RNA Pol II is regulated at
multiple levels by CDK7, CDK9 and CDK12, and transcription of
different genes appears to be more reliant in the activity of only some
of these kinases [13]. For example, inhibition of CDK7 and CDK9
down-regulates the expression of mRNAs with short half-life, such as
the anti-apoptotic mitochondrial gene MCL1 and the oncogenic
transcription factor MYC [35], as observed also in our current study
(Supplementary Figure 4B). On the other hand, CDK12 appears to
be particularly important for the expression of long genes, including
many genes involved in the DNA damage response [44]. We observed
here that the pan-CDK inhibitor AT7519 causes suppression in
mitochondrial OCR and sensitizes cells to inhibition of FAOFigure 3. CDK9 inhibitors are synthetically lethal with inhibitors of fatt
to Perhexiline as measured using oxygen-consumption rate (OCR). A
acute injection of perhexiline (indicated with an arrow). LNCaP cells w
is an average of 3 biological replicates with SEM; t-test was used to ev
μM AT7519 with 10 μM Perhexiline induces DNA damage and cell de
western blotting was used to detect the proteins of interest. Densi
Combination of AT7519 with Perhexiline increases the sub-G1 popula
iodide staining and flow cytometry. Data shown is an average of t
response to AT7519 and Perhexiline treatments. The cumulative activ
36 hours and normalized to cell confluency. Data shown is an average
evaluate the statistical significance. E) Growth rate of cells was re
biological replicates with SEM and t-test was used to assess the sta
single treatment. F) LNCaP cells were treated with NVP2 for 24 hours
assay. Data shown is an average of three technical replicates with STD
NVP2 for 24 hours and samples were analyzed using western blotting.
H) LNCaP cells were treated with 20 nM NVP2 for 4 hours, mRNA iso
to luciferase RNA that was added to each sample in the cell lysis buffe
and t-test was used to assess the statistical significance. I) Growth r
average of four biological replicates with SEM and t-test was used to a
against any single treatment. J) Activation of cell death in response t
Caspases 3 and 7 was recorded using live-cell imaging until 36 hours
biological replicate experiments with SEM and t-test was used to ev(Figs. 1D; 3, D and E). A more thorough characterization of cancer
cells' response to inhibition of specific CDKs is likely to reveal
additional synthetic lethal interactions.
In conclusion, here we show that inhibition of CDK9 activity
leads to suppression of mitochondrial activity and ATP production
in prostate cancer cells. In the future, it will be important to
identify the key mediators of this response. In more general terms,
CDK9 inhibitors could be combined with other inhibitors of the
key energy-sensor pathways to induce apoptosis in prostate cancer
cells.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2019.05.001.
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